Compare AbbVie Inc (ABBV) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Synopsys, Inc. — how do they compare? AbbVie Inc trades at $253.76 (market cap $449.91B), while Synopsys, Inc. trades at $429.97 (market cap $83.61B). The key difference: AbbVie Inc is far larger — about 5.4× Synopsys, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | SNPS | |
|---|---|---|
Market Cap | $449.91B | $83.61B |
Sector | Health | Technology |
52-Week High | $261.07 | $645.59 |
52-Week Low | $184.85 | $380.47 |
Enterprise Value | $513.38B | $91.96B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Synopsys (SNPS) trades at $436.63, down 0.12% on the day, with a bearish technical signal despite strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $3.35 exceeding expectations, and maintains robust gross margins of 73.47%. Recent news highlights the company's strategic pivot toward AI-driven design tools, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with a consensus price target of $558.33 implying 28% upside, driven by AI adoption and market positioning. Key risks include high valuation multiples (P/E of 101.21) and execution challenges in shifting business focus. Investors should weigh growth potential against premium pricing and competitive pressures in the semiconductor software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
